GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (NAS:PROK) » Definitions » Shares Outstanding (Diluted Average)

ProKidney (ProKidney) Shares Outstanding (Diluted Average) : 60.95 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ProKidney Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. ProKidney's average diluted shares outstanding for the quarter that ended in Mar. 2024 was 60.95 Mil.


ProKidney Shares Outstanding (Diluted Average) Historical Data

The historical data trend for ProKidney's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Shares Outstanding (Diluted Average) Chart

ProKidney Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Diluted Average)
186.50 186.50 61.54 61.71

ProKidney Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.54 64.56 61.59 62.16 60.95

ProKidney Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


ProKidney  (NAS:PROK) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


ProKidney Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of ProKidney's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


ProKidney (ProKidney) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (NAS:PROK) » Definitions » Shares Outstanding (Diluted Average)
Traded in Other Exchanges
Address
2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.
Executives
Chamath Palihapitiya 10 percent owner THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Sc Pipe Holdings Llc 10 percent owner 506 SANTA CRUZ AVE., SUITE 300, MENLO PARK CA 94025
Sc Master Holdings, Llc 10 percent owner 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Bruce Culleton officer: EVP, Clinical Development 2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM NC 27103
Aaron Cowen 10 percent owner 540 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Mary Weger officer: Chief People Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
William F Doyle director
Tolerantia, Llc 10 percent owner 110 EAST 59TH STREET, SUITE 3300, NEW YORK NY 10022
Jimenez Santos Jose Ignacio director C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Deepak Jain officer: Chief Operating Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Darin J. Weber officer: SVP of Regulatory Development C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Libbie Parker Mckenzie officer: Chief Medical Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
James Coulston officer: Chief Financial Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Jennifer A. Fox director C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Timothy Bertram director, officer: Chief Executive Officer C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403